Safety and Efficacy of Nerinetide at Year 1 in Participants Enrolled in ESCAPE‐NEXT: A Multicenter, Double‐Blind, Randomized Controlled Trial

 Wil your competent? doctor and hospital be DOING ANYTHING WITH THIS?

Do you prefer your doctor, hospital and board of director's incompetence NOT KNOWING? OR NOT DOING? Your choice; let them be incompetent or demand action!

Safety and Efficacy of Nerinetide at Year 1 in Participants Enrolled in ESCAPE‐NEXT: A Multicenter, Double‐Blind, Randomized Controlled Trial

Corey Adams, PhD https://orcid.org/0009-0001-3645-3154, Kathy Heard, MSc https://orcid.org/0009-0002-4807-2217, 

Yatika Kohli, PhD, Shabnam Vatanpour, PhD https://orcid.org/0000-0002-2398-5039, 

Jorg Berrouschot, MD https://orcid.org/0000-0002-6297-3153, Brian Buck, MD https://orcid.org/0000-0002-7984-6062, 

Andrew Demchuk, MD https://orcid.org/0000-0002-4930-7789, … Show All … the ESCAPE‐NEXT Investigators

Author Info & Affiliations

Journal of the American Heart Association

New online

https://doi.org/10.1161/JAHA.125.044080

 

Abstract

Background

Nerinetide is a neuroprotective agent recently evaluated in the ESCAPE‐NEXT (Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis) trial (NCT04462536), which was terminated after failing to meet its Day 90 primary end point; however, by that time, Year 1 follow‐up outcomes were already available for 513 participants.

Methods

The primary end point at Year 1 was functional independence, defined as modified Rankin Scale score 0 to 2, analyzed by logistic regression adjusted for treatment and baseline covariates. In a post hoc analysis, the interaction between early (<3 hours) versus late (3–12 hours) enrollment window and treatment effect was also tested and the results reported separately by enrollment window.

Results

A total of 513 of 850 participants had documented Year 1 outcomes before study termination, of whom 442 reached their scheduled Year 1 visit. In the nerinetide group, 110 (48.0%) of 229 participants achieved functional independence at Year 1 compared with 102 (47.9%) of 213 in the placebo group (adjusted odds ratio [aOR], 1.12 [95% CI, 0.74–1.71]; P=0.593). There was treatment effect modification by enrollment window (early versus late; Pinteraction=0.044). Among early window participants (n=163), 51 (52.6%) in the nerinetide group and 30 (45.5%) in placebo achieved functional independence (aOR, 2.80 [95% CI, 1.18–6.66], P=0.019) at Year 1. Additionally, the nerinetide group exhibited improved survival (aOR, 2.61 [95% CI, 1.17–5.83], P=0.019). Conversely, no significant clinical benefit of nerinetide at Year 1 was observed among late window participants. Analyses on all 513 participants with documented Year 1 outcomes provided similar results.

Conclusions

Long‐term benefits of early administration of neuroprotection may emerge up to 1 year after stroke.